<DOC>
	<DOCNO>NCT00626795</DOCNO>
	<brief_summary>An international , multi-centre , prospective three arm parallel-group , phase II proof concept study compare efficacy safety two dosage regimen ( BID 7 day TID 7 day ) TD1414 2 % cream one dosage regimen ( BID 7 day ) Bactroban® ( mupirocin ) 2 % cream adult child 2 year age impetigo SITL . Furthermore evaluation pharmacokinetics TD1414 2 % cream TID 7 day perform . A total 664 patient enrolled stepwise manner accord age group start old age group .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability TD1414 2 % Cream Impetigo Secondarily Infected Traumatic Lesions ( SITL )</brief_title>
	<detailed_description />
	<mesh_term>Impetigo</mesh_term>
	<mesh_term>Mupirocin</mesh_term>
	<criteria>Signed date informed consent patient and/or legally acceptable representative obtain Outpatients sex ethnic origin Patients &gt; = 2 year age ( depend study step ) Patients must suffer primary bullous/nonbullous impetigo SITL Presence skin disease near investigational area Immunosuppressed state serious systemic disease Signs and/or symptom systemic infection Presence skin infection/disorder amenable topical antibacterial treatment Presence secondarilyinfected animal/human bite Presence secondarily infect burnwound Topical systemic use medicinal product study investigator opinion could confound evaluation effect study drug Known suspect hypersensitivity TD1414 excipients TD1414 2 % cream Known suspect hypersensitivity mupirocin excipients Bactroban® ( mupirocin ) 2 % cream Participation investigational drug study use ( ) investigational drug ( ) within 30 day 5 halflives ( whichever longer ) prior randomisation Patients previously enrolled/randomised study Abnormal ECG baseline though PR interval may 220 m , QRS interval 110 m QTc interval 450 m</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>